Samsung Bioepis Calls For Improved Education On Biosimilars
White Paper Finds Biosimilars Still Not Clearly Understood By Stakeholders
Renewed efforts are needed to educate healthcare industry stakeholders about biosimilars, Samsung Bioepis has insisted, as the firm published a white paper detailing deficiencies in understanding on the part of patients and healthcare professionals.
You may also be interested in...
Effective communication between doctors and patients when switching from a branded biologic to a biosimilar is needed to overcome the potential ‘nocebo’ effect, insisted Professor Fabrizio Benedetti at a EULAR symposium.
Aspen expects to report significant growth in its continuing operations for the first half of its financial year, following deals with Sandoz and Viatris that have seen the South African firm divest major businesses in Japan and Europe.
Medicines for Europe has called for fresh efforts to bolster the value added medicines sector and “level the playing field” with the US and its 505(b)(2) pathway, launching a new report setting out the three key areas in which greater EU action is needed.